Skip to main content
Premium Trial:

Request an Annual Quote

Gen-Probe Licenses Molecular Dx Technology from Xceed

NEW YORK (GenomeWeb News) – Xceed Molecular announced yesterday that Gen-Probe has taken a non-exclusive license to the firm’s Flow-Thru Chip technology.
 
The Wellesley, Mass.-based company said that Gen-Probe expects to use the technology in developing next-generation multiplexed molecular diagnostics.
 
Under terms of the deal, Gen-Probe will pay up-front licensing and milestone fees to Xceed for non-exclusive access to the chip technology in certain fields. Gen-Probe also has the right to receive co-exclusive rights with Xceed in certain undisclosed sub-fields. San Diego-based Gen-Probe also will make royalty payments to Xceed based on sales and will purchase Xceed’s custom TipChips, Ziplex automated gene expression system, and other Xceed products.
 
“There are many promising applications for moderate-density arrays in clinical diagnostics and other applications, and we believe that Xceed’s technologies in combination with our own technologies will facilitate our entry into these expanding markets,” Dan kacian, executive vice president and chief scientist for Gen-Probe, said in a statement.

The Scan

Study Links Genetic Risk for ADHD With Alzheimer's Disease

A higher polygenic risk score for attention-deficit/hyperactivity disorder is also linked to cognitive decline and Alzheimer's disease, a new study in Molecular Psychiatry finds.

Study Offers Insights Into Role of Structural Variants in Cancer

A new study in Nature using cell lines shows that structural variants can enable oncogene activation.

Computer Model Uses Genetics, Health Data to Predict Mental Disorders

A new model in JAMA Psychiatry finds combining genetic and health record data can predict a mental disorder diagnosis before one is made clinically.

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.